Ullrich, N. J., Prabhu, S. P., Reddy, A. T., Fisher, M. J., Packer, R., Goldman, S., Robison, N. J., Gutmann, D. H., Viskochil, D. H., Allen, J. C., Korf, B., Cantor, A., Cutter, G., Thomas, C., Perentesis, J. P., Mizuno, T., Vinks, A. A., Manley, P. E., Chi, S. N., & Kieran, M. W. (2020). a phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-oncology, 22(10), 1527–1535. http://access.bl.uk/ark:/81055/vdc_100116967979.0x000018